At the time of writing, Fulcrum Therapeutics Inc [FULC] stock is trading at $13.0, up 1.56%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The FULC shares have gain 46.07% over the last week, with a monthly amount glided 55.50%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on July 29, 2025, and elevated its price target to $12. On May 23, 2025, upgrade upgraded it’s rating to Outperform but maintained its price target of $12 on the stock. Cantor Fitzgerald upgraded its rating to a Overweight but stick to its price target of $10 on May 15, 2025. H.C. Wainwright downgraded its rating to a Neutral and reduced its price target to $4 on September 13, 2024. Stifel downgraded its rating to Hold for this stock on September 12, 2024. In a note dated September 12, 2024, RBC Capital Mkts downgraded a Sector Perform rating on this stock and revised its target price from $15 to $4.
For the past year, the stock price of Fulcrum Therapeutics Inc fluctuated between $2.32 and $15.74. Currently, Wall Street analysts expect the stock to reach $20.71 within the next 12 months. Fulcrum Therapeutics Inc [NASDAQ: FULC] shares were valued at $13.0 at the most recent close of the market. An investor can expect a potential return of 59.31% based on the average FULC price forecast.
Analyzing the FULC fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.32 and Total Capital is -0.4. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.66 points at the first support level, and at 12.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.27, and for the 2nd resistance point, it is at 13.53.
Ratios To Look Out For
It is important to note that Fulcrum Therapeutics Inc [NASDAQ:FULC] has a current ratio of 17.70. As well, the Quick Ratio is 17.70, while the Cash Ratio is 4.05.
Transactions by insiders
Recent insider trading involved RA CAPITAL MANAGEMENT, L.P., 10% Owner, that happened on Dec 08 ’25 when 4.18 million shares were sold. 10% Owner, RA Capital Healthcare Fund LP completed a deal on Dec 08 ’25 to buy 4.18 million shares. Meanwhile, Director Gould Robert J sold 15000.0 shares on Nov 19 ’25.
